PTPRC and colitis: To determine whether bortezomib treatment altered the populations of T cells and B cells in mesenteric lymph nodes during DSS-induced colitis, the numbers of CD4+, CD8+, and B220+ cells in mesenteric lymph nodes were assessed by flow cytometry 7 days after DSS administration.